Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer

被引:0
|
作者
Candelieri-Surette, Danielle [1 ]
Hung, Anna [2 ,3 ,4 ]
Lynch, Julie A. [1 ,5 ,6 ]
Pridgen, Kathryn M. [1 ,5 ]
Agiri, Fatai Y. [1 ]
Li, Weiyan [7 ]
Aggarwal, Himani
Anglin-Foote, Tori [1 ,5 ]
Lee, Kyung Min [1 ]
Perez, Cristina [1 ]
Reed, Shelby [2 ,3 ,4 ]
DuVall, Scott L. [1 ,5 ]
Wong, Yu-Ning [8 ,9 ]
Alba, Patrick R. [1 ,5 ]
机构
[1] VA Salt Lake City Hlth Care Syst, VA Informat & Comp Infrastruct, Salt Lake City, UT USA
[2] Durham VA Med Ctr, Durham, NC USA
[3] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Sch Med, Dept Populat Hlth Sci, Durham, NC USA
[5] Univ Utah, Sch Med, Div Epidemiol, Dept Internal Med, Salt Lake City, UT USA
[6] Univ Massachusetts, Dept Nursing & Hlth Sci, Boston, MA USA
[7] AstraZenca Pharmaceut LP, Gaithersburg, MD USA
[8] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA USA
来源
关键词
CLINICAL-TRIALS; RECOMMENDATIONS; DESIGN;
D O I
10.1200/CCI.23.00085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing. Accurately identifying patients with CRPC in electronic health care data is critical for quality observational research, resource allocation, and quality improvement. Previous work in this area has relied on either structured laboratory results and medication data or natural language processing (NLP) methods. However, a computable phenotype using both structured data and NLP identifies these patients with more accuracy. METHODS The Corporate Data Warehouse (CDW) of the Veterans Health Administration (VHA) was used to collect PCa diagnoses, prostate-specific antigen test results, and information regarding patient characteristics and medication use. The final system used for validation and subsequent analysis combined the NLP system and an algorithm of structured laboratory and medication data to identify patients as being diagnosed with CRPC. Patients with both a documented diagnosis of CRPC and a documented diagnosis of metastatic PCa were classified as having mCRPC by this system. RESULTS Among 1.2 million veterans with PCa, the International Classification of Diseases (ICD)-10 diagnosis code for CRPC (Z19.2) identifies 3,791 patients from 2016 when the code was created until 2022, compared with the combined algorithm which identifies 14,103, 10,312 more than ICD-10 codes alone, from 2016 to 2022. The combined algorithm showed a sensitivity of 97.9% and a specificity of 99.2%. CONCLUSION ICD-10 codes proved to be insufficient for capturing CRPC in the VHA CDW data. Using both structured and unstructured data identified more than double the number of patients compared with ICD-10 codes alone. Application of this combined approach drastically improved identification of real-world patients and enables high-quality observational research in mCRPC.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
    Tsao, Che-Kai
    Seng, Sonia
    Oh, William K.
    Galsky, Matthew D.
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 163 - 169
  • [32] Progress in the mechanism and drug development of castration-resistant prostate cancer
    Zuo, Minzan
    Xu, Xi
    Li, Tinghan
    Ge, Raoling
    Li, Zhiyu
    [J]. FUTURE MEDICINAL CHEMISTRY, 2016, 8 (07) : 765 - 788
  • [33] Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
    Feng, Qin
    He, Bin
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [34] Novel chemotherapies in development for management of castration-resistant prostate cancer
    Tewari, Alok K.
    George, Daniel J.
    [J]. CURRENT OPINION IN UROLOGY, 2013, 23 (03) : 220 - 229
  • [35] Emerging treatment options for patients with castration-resistant prostate cancer
    George, Daniel
    Moul, Judd W.
    [J]. PROSTATE, 2012, 72 (03): : 338 - 349
  • [36] Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality
    Spratt, Daniel E.
    Zhang, Chi
    Zumsteg, Zachary S.
    Pei, Xin
    Zhang, Zhigang
    Zelefsky, Michael J.
    [J]. EUROPEAN UROLOGY, 2013, 63 (04) : 709 - 716
  • [37] MLL translocation in two castration-resistant prostate cancer patients
    Chowdry, Rajasree Pia
    Ledet, Elisa
    Asinghe, Lahiru Ran.
    Sartor, Alton Oliver
    [J]. CANADIAN JOURNAL OF UROLOGY, 2016, 23 (05) : 8483 - 8486
  • [38] External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
    Nakano, Kazuhiko
    Komatsu, Kenji
    Kubo, Taro
    Natsui, Shinsuke
    Nukui, Akinori
    Kurokawa, Shinsuke
    Kobayashi, Minoru
    Morita, Tatsuo
    [J]. BMC UROLOGY, 2014, 14
  • [39] External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer
    Kazuhiko Nakano
    Kenji Komatsu
    Taro Kubo
    Shinsuke Natsui
    Akinori Nukui
    Shinsuke Kurokawa
    Minoru Kobayashi
    Tatsuo Morita
    [J]. BMC Urology, 14
  • [40] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    [J]. JAMA NETWORK OPEN, 2024, 7 (08)